|Source||Humanized (from mouse)|
|Biological half-life||20 days|
|(what is this?)|
Mepolizumab (tradename Nucala) is a humanized monoclonal antibody that recognizes interleukin-5 (IL-5). Mepolizumab has been investigated or is under investigation for the treatment of severe eosinophilic asthma, atopic dermatitis, hypereosinophilic syndrome (HES), eosinophilic esophagitis (EoE), nasal polyposis, eosinophilic granulomatosis with polyangiitis (EGPA) (i.e., Churg Strauss syndrome), and chronic obstructive pulmonary disease (COPD). Phase III clinical trials in severe eosinophilic asthma were completed in 2014.
Meplizumab is approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of severe Asthma in patients aged 12 years or older and with an eosinophilic phenotype in combination with other medicines used to treat asthma.
- FDA approves Nucala to treat severe asthma http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471031.htm